Annual report
4548.TEDINET S100R98T
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥34.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥27.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥29.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥4.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.0bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.9bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.4bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥10.8bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.2bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥3.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥75.6bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥75.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥69.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥68.7bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥80.2bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.4bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥8.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥67.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥66.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥63.6bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥59.8bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥73.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥23.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥25.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥8.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥870m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥623m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥40.49 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.32 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.54 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-192.15 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.76 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,232.41 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,179.46 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,127.14 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,059.4 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,294.88 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 88.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.0% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 3.3% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | -16.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 976 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 937 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 913 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 868 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 744 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥22.1bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥25.2bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥21.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥23.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥22.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥0 | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥2.3bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥3.7bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥3.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥2.5bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥3.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥11.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥63.1bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥64.6bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥62.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥62.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥75.2bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.4bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥6.6bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥56.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥58.0bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥57.8bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥55.0bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥68.6bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥18.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥17.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥32.55 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.34 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.86 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-201.73 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.57 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥26 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,039.07 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,031.37 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,024.93 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥975.56 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,216.16 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 89.9% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.8% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.2% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -18.4% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 56,814,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 540 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 531 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 523 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 519 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 514 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| LALreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥634m |
| LALreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥300m |
| LALreportable segment | employees | at 2023-03-31 | 303 pure |
| LALreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥10.7bn |
| LALreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥10.7bn |
| LALreportable segment | segment assets | at 2023-03-31 | ¥13.2bn |
| LALreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Pharmaceuticalreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| Pharmaceuticalreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥851m |
| Pharmaceuticalreportable segment | employees | at 2023-03-31 | 563 pure |
| Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥22.7bn |
| Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥22.7bn |
| Pharmaceuticalreportable segment | segment assets | at 2023-03-31 | ¥62.4bn |
| Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥143m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥33.5bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥33.5bn |
| —segment total | segment assets | at 2023-03-31 | ¥75.6bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| LALreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥732m |
| LALreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥218m |
| LALreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥9.2bn |
| LALreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥9.2bn |
| LALreportable segment | segment assets | at 2022-03-31 | ¥10.8bn |
| LALreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.3bn |
| Pharmaceuticalreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Pharmaceuticalreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥652m |
| Pharmaceuticalreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥25.7bn |
| Pharmaceuticalreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥25.7bn |
| Pharmaceuticalreportable segment | segment assets | at 2022-03-31 | ¥64.5bn |
| Pharmaceuticalreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥870m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥34.9bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥34.9bn |
| —segment total | segment assets | at 2022-03-31 | ¥75.2bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥4.5bn |
| LALreportable segment | employees | at 2023-03-31 | 12 pure |
| Pharmaceuticalreportable segment | employees | at 2023-03-31 | 418 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,588
| Item | Context | Value | Unit |
|---|---|---|---|
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)財務面での取引関係を強化するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)第一生命ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)財務面での取引関係を強化するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)三井住友トラスト・ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)財務面での取引関係を強化するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)無 | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and reasons for exclusion from scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and associates and reasons for not being accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes additional information consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding shares and bonds etc of unconsolidated subsidiaries and associates (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of contract liabilities (text) | CurrentYearInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes securities consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes derivatives consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes retirement benefits consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes share options etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes tax effect accounting consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes revenue recognition consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Description of reportable segments (text) | CurrentYearDuration | Text · Plus | |
| Explanation of measurements of sales profit loss asset liability and other items for each reportable segment (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |